These data clearly suggested that glibenclamide by inhibiting PEPT1 had the ability to attenuate the growth of PDAC cells, thereby implicating that glibenclamide could be used as an anticancer agent for pancreatic cancer. Here, SLC15A1 is linked to familial pancreatic carcinoma.